Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Conditions:   GEP-NET;   Gastroenteropancreatic Neuroendocrine Tumor;   Gastroenteropancreatic Neuroendocrine Tumor Disease;   Neuroendocrine Tumors;   Carcinoid;   Carcinoid Tumor;   Pancreatic NET Interventions:   Drug: RYZ101;   Drug: Everolimus 10 mg;   Drug: Sunitinib 37.5 MG;   Drug: Octreotide LAR 60 MG Injection;   Drug: Lanreotide 120Mg Sa Susp Inj Syringe Sponsor:   RayzeBio, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials